Akeso: Carcinoma, Non-Small-Cell Lung trials
The registry lists 10 Carcinoma, Non-Small-Cell Lung studies with Akeso as lead sponsor. 5 are open to participants now and 0 have results posted.
Phase 1 3Phase 2 4Phase 3 6(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung CancerRecruitingNCT07623356Phase 1/2
- AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) TreatmentNot yet recruitingNCT07158840Phase 2
- Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung CancerRecruitingNCT06928389Phase 3
- A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLCRecruitingNCT06617416Phase 3
- A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung CancerNot yet recruitingNCT05990127Phase 3
- AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung CancerActive, not recruitingNCT05840016Phase 3
- A Trial of AK112 (PD-1/VEGF Bispecific Antibody) in Patients With NSCLCCompletedNCT04900363Phase 1/2
- A Study of AK104 in Patients With Locally Advanced or Metastatic Non-small Cell Lung CancerCompletedNCT04647344Phase 1/2
- A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung CancerCompletedNCT03866993Phase 3
- A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung CancerTerminatedNCT03866980Phase 3